The Board of EXCiPACT asbl is pleased to announce that the IPEC Association
(China) limited has recently become the fifth member of EXCiPACT asbl - the independent, voluntary 3rd party GMP/GDP certification program for manufacturers and distributors of
pharmaceutical excipients - joining the four founding members – IPEC Europe, IPEC Americas, FECC, and PQG (UK).
IPEC Association
(China) was inaugurated in July 2008 to be the voice for the manufacturers, distributors and users of pharmaceutical excipients in China. Presently there are 34 members comprising both local and
international pharmaceuticals excipients suppliers. They have made good progress in developing their relations with the Chinese authorities at both national and local levels and, in recent years,
they have been assisting EXCiPACT in raising its profile in this strategically important pharmaceutical raw materials global supply base. This has resulted in EXCiPACT agreements with two
international Certifying Bodies - BV China and SGS Asia/Pacific - to provide the EXCiPACT Certification Scheme in the region. EXCiPACT certifications have been awarded by BV China in 2015 to Boai
NKY Pharmaceuticals Ltd in 2015 and by SGS to Nanjing Duoyuan Biochemistry Co., Ltd. More are expected this year and beyond as local suppliers realise its benefits in reducing their audit burden
and demonstrating to customers their high quality manufacture and supply.
Kevin McGlue,
President of EXCiPACT, comments that “The EXCiPACT organisation is extremely pleased to welcome IPEC Association (China) as a full member. They have given great assistance to EXCiPACT as we have
sought to establish certification capabilities in the region, and they will now help shape and drive our future plans there. This truly marks EXCiPACT as a globally recognised standard for
excipients.”
Notes for the Editor
EXCiPACT asbl
provides management oversight for the high quality, voluntary international EXCiPACT Certification Scheme that provides for independent 3rd party GMP and/or GDP certification of manufacturers,
suppliers and distributors of pharmaceutical excipients worldwide. The Scheme will ensure patient safety through supplier quality while minimising the overall costs for assessing the excipient
supply chain. It has been operational since early 2013 since when there has been considerable interest among pharmaceutical excipient suppliers, customers and regulators. For further information,
see www.excipact.org or contact info@excipact.org.
EXCiPACT is a registered trademark.